NL-OMON21037招募中不适用
A Phase I Study Assessing the Safety and Performance of SGM-101, a Fluorochrome-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody for the lntraoperative Detection of Neoplastic Lesions in Patients with Cancer of the Rectum or Pancreas
eiden University Medical Center (LUMC) and Centre for Human Drug Research (CHDR), Leiden, the Netherlands0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients aged over 18 years old;
- •2. Patient should be scheduled and eligible for surgery because of a clinical diagnosis of cancer of the
- •rectum or cancer of the pancreas;
排除标准
- •1. Anticancer therapy (e.g. chemotherapy, radiotherapy(except routine pre-operative radiotherapy for
- •rectal cancer), targeted therapy, concomitant systemic immune therapy, or any experimental therapy)
- •within 4 weeks before inclusion;
研究者
相似试验
已完成
不适用
A Phase I Study Assessing the Safety and Performance of SGM-101, a Fluorochrome-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody for the Intraoperative Detection of Neoplastic Lesions in Patients with Cancer of the Colorectum or PancreasNL-OMON47359Surgimab85
已完成
不适用
A phase I study assessing the safety and performance of VB5-845D-800CW, an anti-Epcam fluorescent agent, for the intraoperative detection of gastrointestinal canceresophageal/gastric- or colorectal cancer10017990NL-OMON48830eids Universitair Medisch Centrum34
招募中
1 期
Phase I study of MTC001 in patients with chronic ischemic heart failureJPRN-jRCT2033210078Machino Takeshi6
撤回
1 期
A Phase I/Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of DSM265 in Healthy Subjects and to Assess the Antimalarial Activity of DSM265 in Healthy Subjects with an Induced Blood Stage Plasmodium falciparum Infection.PART 3.Infection - Other infectious diseasesMalariaACTRN12613000533796CPR Pharma Services24
已完成
1 期
A Phase I/Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of DSM265 in Healthy Subjects and to Assess the Antimalarial Activity of DSM265 in Healthy Subjects with an Induced Blood Stage Plasmodium falciparum Infection.PART 1.MalariaACTRN12613000522718CPR Pharma Services73